Total neoadjuvant therapy for rectal cancer in the cao/aro/aio-12 randomized phase 2 trial: early surrogate endpoints revisited

HIGHLIGHTS

• who: Markus Diefenhardt and colleagues from the Department of Radiotherapy and Oncology, University of Frankfurt, Frankfurt, Germany have published the article: Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited, in the Journal: (JOURNAL) of 19/01/2015
• what: PCR, TRG and NAR score were prognostic parameters for DFS in the entire cohort as well as in both arms of the CAO/ARO/AIO-12 trial and likely reflect (and unmask) different tumor biology.
• how: The authors examined the prognostic role of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.